| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 14
| Issue : 3 | Page : 128-138 |
|
|
In vitro anti-plasmodial activity of new synthetic derivatives of 1-(heteroaryl)-2- ((5-nitroheteroaryl)methylene) hydrazine
Azar Tahghighi1, Akram Abouie Mehrizi2, Sedigheh Zakeri2
1 Malaria and Vector Research Group, Biotechnology Research Center; Department of Clinical Research, Pasteur Institute of Iran, Tehran, Iran
2 Malaria and Vector Research Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Correspondence Address:
Akram Abouie Mehrizi
Malaria and Vector Research Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran
Iran
 Source of Support: It was supported by the grant (No. 852) from Pasteur Institute of Iran to A. A. Mehrizi, Conflict of Interest: None  | 3 |
DOI: 10.4103/1995-7645.306740
|
|
|
Objective: To evaluate new compounds synthesized by integrating quinoline, quinazoline, and acridine rings with the active moiety of (5-nitroheteroaryl) methylene hydrazine.
Methods: A new series of compounds (1a, 1b, 2a, 2b, 3a, and 3b) were synthesized and evaluated for cytotoxicity against COS-7 cells using the MTT assay. In vitro anti-plasmodial activity of the compounds was measured against CQ-sensitive (3D7) and CQ-resistant (K1) Plasmodium (P.) falciparum strains. β-hematin assay was performed to assess the inhibitory effects of β-hematin formation for new compounds.
Results: The synthetic compounds had anti-plasmodial activity against blood-stage of 3D7 [IC50=(0.328-5.483) μM] and K1 [IC50=(0.622-7.746) μM] strains of P. falciparum, with no cytotoxicity against COS-7 cells in effective doses. Compounds 1a, 1b, and 2b were the most effective derivatives against P. falciparum 3D7 and K1 strains. Based on the β-hematin assay, the inhibition of β-hematin formation is the main mechanism of the inhibitory effect of these compounds.
Conclusions: The synthetic compounds could inhibit the erythrocytic stages of CQ-sensitive and resistant P. falciparum strains without toxicity towards mammalian cells. Compounds 1b, 2a, and 2b had comparable anti-plasmodial activity against both CQ-sensitive (3D7) and resistant (K1) P. falciparum strains. These compounds may be promising lead structures for the development of new anti-malarial drugs.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
